Clinical Trial Update: Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing safety and tolerability of HSC835 in patients with hematological malignancies undergoing single umbilical cord blood tra…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Multiple Myeloma
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma

Drugs mentioned

• HSC835

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning | Phase 2 | Status: COMPLETED | Results posted: 2017-08-10